HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $77 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Legend Biotech (NASDAQ:LEGN) and maintained a $77 price target.
May 22, 2023 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor reiterated a Buy rating on Legend Biotech and maintained a $77 price target.
The reiteration of a Buy rating and maintenance of a $77 price target by HC Wainwright & Co. analyst Mitchell Kapoor indicates a positive outlook for Legend Biotech. This news is likely to have a positive short-term impact on the stock price, as it shows confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100